10 September 2019
Visiongain has launched a new pharma report Global Oncology Pricing, Reimbursement & Market Access 2019-2029: US, Canada, Germany, France, UK, Italy, Spain, Japan, Australia, Brazil, Russia, India, China.
This report provides analysis and evaluation of the current and prospective economic burden of cancer treatment in US, Canada, Germany, France, UK, Italy, Spain, Japan, Australia, Brazil, Russia, India, China. This report also outlines historical and current healthcare status for the selected markets with respect to expenditures along with the healthcare system that governs medical access.
In this report, we provide comprehensive view on some of the trends for top-seller oncology drugs including payer’s perspective on cancer outcomes, impact of these high cost drugs, standard guidelines preferred for different cancers, availability and costs of oncology therapeutics and complexity in cancer treatments, epidemiology of different cancer types.
The lead analyst of the report commented "Although price is still the most important competitive advantage for a biosimilar company, current discount rates are not enough to automatically convince the key stakeholders of a biosimilar’s value. The impact of biosimilars on drug costs and healthcare will be established as more of these therapies are introduced in the market. For this, it is important that stakeholders take steps now to understand the potential and issues related to biosimilars, arming themselves with right tools and data to effectively manage their dispensing and coverage and pave a successful way for saving economic burden of these expensive biologic treatments."
Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to email@example.com or call her on +44 (0) 20 7549 9987.
Visiongain is one of the fastest growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports focusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.
Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.
Deviating from protocols raises the danger of missing or delaying data collection from current investigations. This highlights the growing importance of digital medicine, which is being aided by advancements in cloud, mobile, and IoT technology.
11 October 2021
High performance HPC and supercomputing technology have evolved substantially in China in the last decades, leading to extraordinary accomplishments. HPC-based and combined pharmaceutical chemical and computational biology computational discovery and design has become a significant technique in drug research and development and is sponsored financially by the Chinese government.
07 October 2021
Many health-care organizations are seeing organic growth at levels that their supply networks were never designed to handle. Others are frantically attempting to integrate diverse technology and procedures as part of a consolidation effort.
06 October 2021
Rise in prevalence of meningitis, increasing initiatives by government and regulatory authorities coupled strong funding support from non-profit organizations is expected to drive the global meningococcal vaccines market